Prospective, randomized, controlled, trial to Assess ASA DOSing by Body Mass Index in HEalthy Volunteers (DOSE Study).

In healthy male and female participants administered ASA for 14 days, obesity is not associated with increased basal platelet activation or ASA resistance. ASA 81 mg was significantly less effective in reducing platelet aggregation compared to ASA 325 mg and 500 mg, independent of BMI.